In recent years, the U.S. Food and Drug Administration (FDA) has demonstrated its ongoing commitment to support advancements in the field of neurotechnology. Its approach underscores the agency’s willingness to consider submissions for medical devices such as Deep Brain Stimulation (DBS) and Transcranial Magnetic Stimulation (TMS).
DBS and TMS devices use different approaches to stimulate the brain, both invasively and non-invasively. While the former have been available since 2002, the latter only became available a decade later in 2013. However, the approval trajectory for these devices shows the FDA’s dedication to embracing the growth in this area of medicine.
DBS devices function by delivering controlled electrical signals directly to targeted areas of the brain, while TMS devices use a magnetic field to generate electrical currents within the brain without the need for surgical implementation.
Such devices, amidst proving crucial in the treatment and management of conditions like Parkinson’s disease, depression, and epilepsy, have recently been approved with updated functionality and expanded claims. This indicates a notable responsiveness on the part of the FDA to consider novel features and broader claims for these types of medical devices.
Read the full report on this development via this link.